Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.
J Infect Dis. 2011 Nov 15;204(10):1475-82. doi: 10.1093/infdis/jir561. Epub 2011 Sep 23.
The safety and immunogenicity of live, attenuated influenza vaccine (LAIV) has not been compared to that of the standard trivalent inactivated vaccine (TIV) in children with cancer.
Randomized study of LAIV versus TIV in children with cancer, age 2-21 years, vaccinated according to recommendations based on age and prior vaccination. Data on reactogenicity and other adverse events and blood and nasal swab samples were obtained following vaccination.
Fifty-five eligible subjects (mean age, 10.4 years) received vaccine (28 LAIV/27 TIV). Both vaccines were well tolerated. Rhinorrhea reported within 10 days of vaccination was similar in both groups (36% LAIV vs 33% TIV, P > .999). Ten LAIV recipients shed virus; the latest viral shedding was detected 7 days after vaccination. Immunogenicity data were available for 52 subjects, or 26 in each group. TIV induced significantly higher postvaccination geometric mean titers against influenza A viruses (P < .001), greater seroprotection against influenza A/H1N1 (P = .01), and greater seroconversion against A/H3N2 (P = .004), compared with LAIV. No differences after vaccination were observed against influenza B viruses.
As expected, serum antibody response against influenza A strains were greater with TIV than with LAIV in children with cancer. Both vaccines were well tolerated, and prolonged viral shedding after LAIV was not detected.
NCT00906750.
尚未比较减毒活流感疫苗（LAIV）与标准三价灭活流感疫苗（TIV）在癌症儿童中的安全性和免疫原性。
对年龄在 2-21 岁的癌症儿童进行 LAIV 与 TIV 的随机研究，根据年龄和既往接种情况建议进行接种。接种后获取关于不良反应和其他不良事件以及血液和鼻拭子样本的数据。
55 名符合条件的受试者（平均年龄 10.4 岁）接受了疫苗接种（28 名 LAIV/27 名 TIV）。两种疫苗均耐受良好。接种后 10 天内报告的流涕在两组中相似（LAIV 为 36%，TIV 为 33%，P >.999）。10 名 LAIV 受种者病毒排出；接种后 7 天检测到最晚的病毒排出。52 名受试者（每组 26 名）有免疫原性数据。TIV 诱导的流感 A 病毒接种后几何平均滴度显著高于 LAIV（P <.001），对 A/H1N1 的血清保护作用更强（P =.01），对 A/H3N2 的血清转化率更高（P =.004），而对流感 B 病毒无差异。
与预期的一样，癌症儿童中 TIV 引起的针对流感 A 株的血清抗体反应大于 LAIV。两种疫苗均耐受良好，未发现 LAIV 接种后病毒持续排出。
NCT00906750。
